A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo

Acute leukemia is a highly heterogeneous disease; therefore, combination therapy is commonly used for patient treatment. Drug–drug interaction is a major concern of combined therapy; hence, dual/multi-target inhibitors have become a dominant approach for cancer drug development. HDACs and HSP90 are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Wen, Chao, Min-Wu, Tu, Huang-Ju, Chen, Liang-Chieh, Hsu, Kai-Cheng, Liou, Jing-Ping, Yang, Chia-Ron, Yen, Shih-Chung, HuangFu, Wei-Chun, Pan, Shiow-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119482/
https://www.ncbi.nlm.nih.gov/pubmed/33986242
http://dx.doi.org/10.1038/s41389-021-00331-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119482/
https://www.ncbi.nlm.nih.gov/pubmed/33986242
http://dx.doi.org/10.1038/s41389-021-00331-0

Ejemplares similares